Edgeline Holdings Announces Donald Picker Has Joined the Company as Its Acting Chief Operating Officer

Business Wire, Jan 8, 2008

HOUSTON -- Edgeline Holdings, Inc. (OTCBB:ELHI) announced today that Donald Picker has joined its subsidiary, Intertech Bio, as its acting Chief Operating Officer. Dr. Picker will assume the role of acting COO as of January 2008.

Dr. Picker has extensive hands-on experience in bringing drugs from concept to market through all phases of research, preclinical and clinical development in a small company environment. Most recently Dr. Picker was President of Tapestry Pharmaceuticals where he built the clinical development group and brought its lead cancer drug into several Phase II clinical trials. Previously, he was the Executive VP of R&D at Callisto Pharmaceuticals where he was responsible for licensing their two lead cancer programs and oncology preclinical programs and bringing these cancer drugs into Phase I and Phase II development. Dr. Picker in his career has also held senior executive positions at other companies where he was responsible for bringing numerous drug candidates into clinical development. He and his group were responsible for the development of Carboplatin, one of the world's leading cancer drugs currently in use with annual sales of over $500 million. He was also responsible for Satraplatin and Picoplatin, third generation platinum drugs which are currently in late stage clinical development. Although most of his experience has been in oncology drug development, he has also been involved in the areas of infectious disease, cardiovascular, dermatological and gastrointestinal pharmaceutical discovery and development.

Leonard Ivins, CEO of Edgeline Holdings, stated, "We are excited to have someone with Dr. Picker's extensive experience and track record in oncology to lead the development of the cancer pipeline that Edgeline Holdings has identified for licensing. The ability to bring these candidates as quickly as possible into development should build value for the shareholders of the company."

Recent News

Edgeline Holdings, Inc. announced that it has signed an exclusive option agreement with The University of Texas M.D. Anderson Cancer Center which provides the company the right to negotiate a license for five technologies relating to the treatment of various cancers over a nine month period.

Additionally, Edgeline Holdings announced it has signed a Joint Development Agreement with Houston Pharmaceuticals to assist the company in obtaining a license for certain patents, several of which are from the University of Mississippi and the University of Louisiana. Houston Pharmaceutical will continue collaborations with both universities and assist them in securing grants on behalf of the company.

About Edgeline Holdings, Inc.

Headquartered in Houston, Texas, Edgeline Holdings, Inc. is a publicly traded company that specializes in the area of discovering and acquiring leading-edge niche technologies. Through its subsidiaries, the company currently has three areas of focus which include biotechnology, oil and gas and information technology. Edgeline looks to add intellectual property across its subsidiaries and further develop these technologies to ultimately maximize the value of such technologies by bringing them to market through licensing arrangements and partnerships.

Safe Harbor Statement

This press release contains statements that may constitute forward-looking statements, including the company's ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Edgeline's future business and financial results, refer to Edgeline's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2007 and Annual Report on Form 10-KSB for the year ended March 31, 2007. Edgeline Holdings undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.